Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Antidote and XpertPatient.com partner to empower those new to a cancer diagnosis to easily find clinical trials


News provided by

Antidote

Feb 07, 2023, 09:00 ET

Share this article

Share toX

Share this article

Share toX

Antidote and XpertPatient logos
Antidote and XpertPatient logos

Antidote's best-in-class clinical trial search engine will be featured across XpertPatient.com, an award-winning educational website, helping cancer patients better understand and seamlessly match to medical research opportunities.

MIAMI and CHATHAM, N.J., Feb. 7, 2023 /PRNewswire-PRWeb/ -- Antidote Technologies ("Antidote"), a digital patient engagement company that connects clinical trial sponsors and patients, and XpertPatient.com, an award-winning website that provides support to newly-diagnosed cancer patients, today announced a partnership to provide the XpertPatient.com community with access to Antidote Match™, a patient-friendly clinical trial search that currently powers clinical trial matching for 300+ patient organizations.

The addition of Antidote Match to XpertPatient.com will increase patient understanding of clinical trials and help build awareness of all of their treatment options, from those currently FDA-approved to those in the research stages. Together, we are ensuring that those on a cancer journey are informed about research opportunities, which will ultimately lead to increased participation, better quality clinical trial results, and new treatments coming to the market faster.

“By joining forces, we are providing those new to cancer with a more holistic view of their options, building confidence and enabling them to be true partners to their doctors during treatment planning.” - Risa Arin, Founder and CEO, XpertPatient.com

Post this

Antidote is currently powering clinical trial search across the treatment option pages of XpertPatient.com in three cancer centers, breast cancer, prostate cancer, and lung cancer, and will be added to the site's remaining ten cancer centers by the summer of 2023.

There are an estimated 18.1 million cancer cases around the world, and cancer is the second leading cause of death in the United States. For these patients, new and better treatment options are critical — but currently, only 8% of cancer patients are enrolled in treatment trials. As discussed in a recent podcast, Antidote and XpertPatient.com recognize the importance of providing educational materials about treatment options and clinical trial participation to those who have been diagnosed with cancer.

"Antidote is providing an easy-to-use clinical trial matching tool specific to each of XpertPatient.com's 13 online cancer centers. Our UX team has integrated the tool into a simple, yet rich, learning experience for our visitors," said Risa Arin, Founder and CEO of XpertPatient.com. "By joining forces, we are providing those new to cancer with a more holistic view of their options, building confidence and enabling them to be true partners to their doctors during treatment planning."

Importantly, Antidote and XpertPatient.com are also committed to ensuring that the individuals taking part in clinical trials are reflective of the real-world patient population. Clinical trials as a whole are often lacking in their representation of racial and ethnic minorities, and cancer trials have exhibited a clear tendency to be less diverse than the average patient population — which can have serious implications for communities of color. For example, the mortality rate for black women with breast cancer is 40% higher than that of white women. While there are many factors involved in statistics like this, creating more inclusive patient recruitment for clinical trials is one of the key ways to address these disparities.

"Providing patients with the ability to discover clinical trial opportunities is at the core of what Antidote does," said Laurent Schockmel, CEO of Antidote. "XpertPatient.com's strong presence in the cancer community makes them an ideal partner for Antidote, and we are delighted that they have selected our Match technology as an important resource for their communities."

A lack of enrollment is a major problem facing the entire medical research industry. By providing patients with a simple and streamlined way to find clinical trials for which they may be eligible, the partnership between Antidote and XpertPatient.com will serve to assist patients and advance the future of oncology breakthroughs.

About Antidote

Antidote is a digital health company on a mission to accelerate medical research. In a world where 80% of clinical trials are delayed or closed due to a shortage of suitable participants, Antidote uses precision recruitment to match the right patients with the right trials, striking the right balance between technology and human touch to deliver high-quality patient engagement. This is achieved through the integration of data-driven technologies, digital expertise, deep domain experience, an extensive, diverse partner network, and personalized patient and site services. Antidote was launched as TrialReach and is based in the US and UK. For more information, please visit http://www.antidote.me.

About XpertPatient.com

XpertPatient.com is an award-winning, next-gen website empowering cancer patients to become "cancer smart" and to feel confident being true partners to their doctors and nurses. They are committed to helping new cancer patients understand their diagnosis and the differences between the latest oncological treatment options available. By guiding visitors through a personalized website experience, XpertPatient.com provides resources, educational material, and community for patients, making a complex and overwhelming life situation easier to navigate and understand. For more information, visit http://www.xpertpatient.com.

Media Contacts

Faith Brewitt
[email protected]
+1 603 686 0913

Lisa Conroy
Head of Communications, Antidote
[email protected]
+1 215 872 2917

Media Contact

Lisa Conroy, Antidote, 1 2158-72-2917, [email protected]

Faith Brewitt, XpertPatient, 603 686 0913, [email protected]

Twitter

SOURCE Antidote

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.